Filing Details

Accession Number:
0001415889-21-002207
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-29 21:36:24
Reporting Period:
2021-04-27
Accepted Time:
2021-04-29 21:36:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1411906 Ampio Pharmaceuticals Inc. AMPE Pharmaceutical Preparations (2834) 260179592
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1717673 Holli Cherevka C/O Ampio Pharmaceuticals, Inc.
373 Inverness Parkway, Suite 200
Englewood CO 80112
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-27 30,000 $0.51 30,000 No 4 M Direct
Common Stock Acquisiton 2021-04-27 44,631 $0.51 74,631 No 4 M Direct
Common Stock Disposition 2021-04-27 74,631 $2.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-04-27 30,000 $0.51 30,000 $0.51
Common Stock Stock Option (Right to Buy) Disposition 2021-04-27 44,631 $0.51 44,631 $0.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2027-08-08 No 4 M Direct
155,369 2029-09-16 No 4 M Direct
Footnotes
  1. The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 12, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.005, inclusive. The reporting person undertakes to provide to Ampio Pharmaceuticals, Inc., any security holder of Ampio Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. Options were granted and previously reported on a Form 4 filed on September 21, 2017, where all of the options reported vested and became exercisable immediately.
  4. Options were granted and previously reported on a Form 4 filed on September 18, 2019, where 50% of the options awarded vested and became exercisable on the grant date of September 16, 2019 and the other 50% of the options awarded vested and became exercisable on the first anniversary of the grant date.